trial

Varenicline Adjunctive Treatment in Schizophrenia

NCTId NCT00492349
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 91 (actual)
Sponsored by University of Maryland, Baltimore County
Primary completion 2010-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
91 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2007-05
Primary completion
2010-05
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Varenicline

Sponsors

University of Maryland, Baltimore CountyLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
L. Elliot Hong, M.D.Principal Investigator

Sites

3 total
Baltimore, United StatesBaltimore, United StatesBaltimore, United States

Facts & assertions

4 sourced
Enrollment
91
Phase
PHASE4
Primary Completion Date
2010-05
Status
COMPLETED
relationships
The graph out of here
drug
Varenicline
drug
lead_sponsor
University of Maryland, Baltimore County
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophreniform Disorder
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
L. Elliot Hong, M.D.
person